Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study

• Published in: Endocrine-related cancer Vol. 14; no. 2; pp. 473 - 482
• Main Authors: Zatelli, Maria Chiara, Torta, Mirella, Leon, Antonette, Ambrosio, Maria Rosaria, Gion, Massimo, Tomassetti, Paola, De Braud, Filippo, Delle Fave, Gianfranco, Dogliotti, Luigi, Uberti, Ettore C degli
• Format: Journal Article
• Language: English
• Published: England BioScientifica 01.06.2007
• Subjects: Adult; Biomarkers, Tumor - blood; Chromogranin A - blood; Enzyme-Linked Immunosorbent Assay; Female; Gastrointestinal Neoplasms - diagnosis; Gastrointestinal Neoplasms - pathology; Humans; Italy; Male; Middle Aged; Neuroendocrine Tumors - diagnosis; Neuroendocrine Tumors - secondary; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - pathology; Italy
• ISSN: 1351-0088; 1479-6821
• DOI: 10.1677/ERC-07-0001

Elevated circulating chromogranin A (CgA) levels are found in neuroendocrine tumors (NETs), but the diagnostic usefulness of this marker is still debatable. To assess the role of CgA for the diagnosis of gastroenteropancreatic (GEP) NETs and the identification of metastatic patients, an Italian multicenter observational study has been performed. CgA was evaluated in 202 GEP NET patients by IRMA and ELISA. The cutoffs for diagnosis and presence of metastases were identified by receiver-operating characteristic (ROC) curve. We found good correlation between IRMA and ELISA. The ROC analysis identified a cutoff of 53 ng/ml for IRMA and 16 U/l for ELISA as discriminating between controls and patients with active disease (sensitivity 71.3 and 84%; specificity 71 and 85% respectively). Metastases were present in 123 patients, having significantly higher CgA levels than patients without metastases. ROC analysis identified a cutoff of 146 ng/ml for IRMA and 67.3 U/l for ELISA as discriminating between patients with and without metastases (sensitivity 57 and 63.3%; specificity 55.6 and 71.4% respectively). For pancreatic NETs positive and negative predictive values were 84 and 78% respectively (90% specificity and 68% sensitivity). We found lower CgA levels in patients with extensive metastatic spread than in those with liver metastases only. These data assess the role of CgA evaluation in GEP NETs, and demonstrate that higher CgA levels associate with metastatic disease, confirming that CgA levels can provide a helpful practical biochemical marker for the clinical management of NETs, but with low sensitivity and specificity.